It was a great pleasure to meet with Anthony Tang to discuss the RAFT-AF trial results investigating the safety and efficacy of catheter ablation-based rhythm control compared with rate control for the treatment of patients with atrial fibrillation and heart failure, presented at ACC 2021.
- What were the aims and design of the RAFT study? (0:19)
- What were the key inclusion criteria of the study? (0:44)
- Could you tell us a little about the study findings in terms of primary and secondary outcomes, and the reasons for early termination of the study? (1:44)
- How did these findings compare with other studies comparing rhythm-control and rate-control strategies among patients with atrial fibrillation and heart failure? (5:58)
- What are the implications of these findings for the management of patients with atrial fibrillation and heart failure, and what future studies are needed? (7:50)
Speaker disclosures: Anthony Tang has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed during a remote video call with Professor Anthony Tang as a highlight of ACC 2021, May 2021.
Share this Video
Related Videos In Heart Failure
Roxana Mehran, ESC 2021 – the PARADISE-MI Trial
Dr Roxana Mehran (Director of Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine, Mount Sinai Hospital, New York City, NY, USA) kindly shared her thoughts on the the PARADISE-MI trial (NCT02924727) from from the virtual ESC Congress 2021. Questions What has been the impact of angiotensin receptor-neprilysin inhibitors (ARNIs) on the treatment of […]
Gilles Montalescot, ESC 2021 – the QUORUM Clinical Study
Prof. Gilles Montalescot (Professor, Pitié-Salpêtrière Hospital, Paris, France) kindly shared his thoughts on the difficulty of treating heart failure after acute myocardial infarction, the use of firibastat and the QUORUM clinical study (NCT03715998) from the virtual ESC Congress 2021. Questions Why does heart failure after acute myocardial infarction remain so challenging to treat? (0.19) Could […]
Diana Bonderman, ESC 2021 – the DYNAMIC Study
Prof. Diana Bonderman (Cardiologist, Medical University of Vienna, Vienna, Austria) kindly shared her thoughts on the current challenges in the treatment of pulmonary hypertension and heart failure with preserved ejection fraction, the mechanism and use of riociguat, and the DYNAMIC study (NCT02744339) from from the virtual ESC Congress 2021. Questions What are the challenges in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!